Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? (Q44686245)

5 December 2017

title

Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? (English)

1 reference

5 December 2017

5

1 reference

5 December 2017

4

Terho Lehtimäki

1 reference

5 December 2017

Veli-Pekka Valkonen

1

1 reference

5 December 2017

Juha Laakso

2

1 reference

5 December 2017

Hannu Päivä

3

1 reference

5 December 2017

Marja Isomustajärvi

6

1 reference

5 December 2017

Inkeri Ruokonen

7

1 reference

5 December 2017

Jukka T Salonen

8

1 reference

5 December 2017

Reijo Laaksonen

9

1 reference

5 December 2017

publication date

1 December 2003

1 reference

Atherosclerosis. Supplements

5 December 2017

published in

1 reference

5 December 2017

volume

4

1 reference

5 December 2017

issue

4

1 reference

5 December 2017

page(s)

19-22

1 reference

Regulatory functions of the vascular endothelium

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Biological significance of endogenous methylarginines that inhibit nitric oxide synthases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Design of isoform-selective inhibitors of nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Elevatedl-Arginine/Dimethylarginine Ratio Contributes to Enhanced Systemic NO Production by Dietaryl-Arginine in Hypercholesterolemic Rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2803%2900029-1

7 January 2021

10.1016/S1567-5688(03)00029-1

Identifiers

DOI

1 reference

5 December 2017

1 reference